Table 2.

Frequencies of patients with a SFP≤0.100 FU/mo in the 1^st year post-OLT, in relationship with a selection of demographic and clinical variables

	All patients (n=90) FU/mo≤0.100 n=70	HCV-positive patients (n=55) FU/mo≤0.100 n=39	HCV-negative patients (n=35) FU/mo≤0.100 n=31
Recipient male gender (n=63)	53a	29	24
Donor male gender (n=53)	40	19	21
Recipient age ≤55 yr (n=54)	42	19	23
Donor age ≤45 yr (n=54)	47c	29e	18
Pre-OLT BMI >26.0 kg/m2 (n=35)	32b	16d	16
Tacrolimus therapy (n=69)	56	31	25
Corticosteroid tapering >90 d (n=47)	39	25	14
Diabetes mellitus (n=24)	17	10	7

FU/mo: fibrosis units per month, HCV: hepatitis C virus, BMI: body mass index,

^aP<0.05 vs recipient female gender,

^bP<0.02 vs pre-OLT BMI ≤26 kg/m²,

^cP<0.01 vs donor age >45 yr;

^dP<0.05 vs pre-OLT BMI ≤26 kg/m² (comparison of cross-product ratios between HCV positive and negative patients: P<0.05),

^eP<0.001